Skip to content
Subscriber Only
Business
Pursuits

Aimmune’s Peanut Allergy Drug Desensitizes Patients in Trial

Aimmune Therapeutics Inc.’s treatment for peanut allergy successfully desensitized patients in a midstage trial. If eventually approved, it would be the first oral drug for the condition.

The treatment, known as AR101, would be used to protect people with peanut allergies from a small, accidental exposure, such as what might happen in a restaurant.